[Edaily Reporter SONG YOUNG-DOO ] NIBEC CO., LTD.(138610)Naibec has released preclinical data on its obesity treatment candidate “Rigenotide” related to fatty liver and muscle and announced its future plans.
According to NIBEC CO., LTD. on the 17th, the company presented the research results on Rigenotide as a poster at “ObesityWeek 2026,” an obesity conference held in Washington, D.C., from the 14th through the 17th. The research team examined the effects of Rigenotide using animal models of obesity induced by a high-fat diet, as well as adipocytes, hepatocytes, and myocytes. Some indicators were compared with those of the GLP-1 receptor agonist treatment group.
In the obese animal model, fat and collagen accumulation in the liver decreased, while muscle fiber cross-sectional area increased. NIBEC CO., LTD. plans to verify, in a Phase 2 clinical trial, both the therapeutic efficacy of RegenoTide on its own and the benefits of adding it to existing glucagon-like peptide-1 (GLP-1) class therapies.
Reduced Liver Fat and Collagen Deposition; Increased Muscle Fiber Cross-Sectional Area
In obese animal models, fat accumulation and collagen deposition in liver tissue decreased following administration of Rigenotide. The expression area of alpha-smooth muscle actin (α-SMA), a marker associated with liver fibrosis, was also smaller than that in the GLP-1 receptor agonist control group. In experiments with hepatocytes in which fat accumulation was induced by fatty acids, fat accumulation was significantly reduced in the RegenoTide-treated group. Under the same conditions, the reduction in the GLP-1 receptor agonist control group was not statistically significant.
In muscle, the muscle fiber cross-sectional area in the Rigenotide-treated group was larger than that in the obese control group. Expression of Pax7, a marker of satellite cells involved in muscle regeneration, was also higher. In a cellular model in which muscle atrophy was induced by dexamethasone, the length and diameter of muscle cells—which had become shorter and thinner—showed signs of recovery.
Regarding lipid metabolism, the mitochondrial oxygen consumption rate and maximum respiratory rate were significantly higher than those in the GLP-1 receptor agonist comparison group. NIBEC CO., LTD. explained that these results support the potential of Rigenotide to promote fatty acid oxidation.
Phase 2 to Evaluate Monotherapy and Combination Therapy… Plans to Verify Additional Improvements in Humans
NIBEC CO., LTD. plans to proceed with development in Phase 2 clinical trials by evaluating both RegenoTide monotherapy and combination therapy with GLP-1 receptor agonists. For monotherapy, the company plans to assess therapeutic effects related to obesity and metabolic disorders, while for combination therapy, it will investigate whether adding RegenoTide to existing GLP-1 receptor agonists results in further improvements in body fat and muscle-related markers.
The changes in liver and muscle markers disclosed in this announcement were observed in animal and cellular studies. The challenge for subsequent clinical trials will be to verify whether Regenotide can preserve muscle mass or improve liver-related markers during the weight loss process in actual patients.
A NIBEC CO., LTD. official stated, “This study has provided concrete preclinical evidence that Rigenotide can influence fatty liver-related markers and muscle regeneration while regulating lipid metabolism,” adding, “In future clinical trials, we will verify the therapeutic potential of monotherapy and the additional benefits of combination therapy with GLP-1 agonists, respectively, to advance the development of a differentiated obesity treatment.”